• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

    1/18/22 11:30:02 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GTBP alert in real time by email
    SC 13G/A 1 ea154093-13ga6alpha_gtbio.htm AMENDMENT NO. 6 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 6)

     

    GT BIOPHARMA, INC.

     

    (Name of Issuer)

     

    COMMON STOCK

     

    (Title of Class of Securities)

     

    36254L100

     

    (CUSIP Number)

     

    December 31, 2021

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s)

     

    Page 1 of 5 Pages

     

     

     

     

     

     

    CUSIP No. 36254L100

      13G Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSON
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
       
      Alpha Capital Anstalt
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
      (a) ☐
      (b) ☐
    3.   SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Liechtenstein

    5.

    SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 265,232 shares (1)

       
    6. SHARED VOTING POWER – None
       
    7. SOLE DISPOSITIVE POWER – 265,232 shares (1)
       
    8. SHARED DISPOSITIVE POWER – None
       

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -  
         
      265,232 shares (1)  
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES  
      CERTAIN SHARES ☐
     

     
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
         
      0.867%  
    12. TYPE OF REPORTING PERSON  
         
      CO  

      

    (1)Based on 30,582,354 shares outstanding as of November 10, 2021 as disclosed in Form 10-Q filed on November 10, 2021 for the quarter ended September 30, 2021.

     

     

     

     

    CUSIP No. 36254L100

      13G Page 3 of 5 Pages

     

    ITEM 1 (a) NAME OF ISSUER: GT Biopharma, Inc.

     

    ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

     

    4830 West Kennedy Blvd, Suite 600, Tampa, FL 33609

     

    ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    Altenbach 8, FL-9490 Vaduz, Liechtenstein

     

    ITEM 2 (c) CITIZENSHIP: Liechtenstein

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock

     

    ITEM 2 (e) CUSIP NUMBER: 36254L100

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4 OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 265,232 shares (1)

     

    (b) PERCENT OF CLASS: 0.867%

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    265,232 shares (1)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    265,232 shares (1)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

     

    CUSIP No. 36254L100

      13G Page 4 of 5 Pages

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Alpha Capital Anstalt’s ownership is now below 5%.

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9 NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

     

    CUSIP No. 36254L100

      13G Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    January 18, 2022

      (Date)
       
      /s/ Konrad Ackermann
      (Signature)
       
      Konrad Ackermann, Director
      (Name/Title)

     

     

     

     

     

    Get the next $GTBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GTBP

    DatePrice TargetRatingAnalyst
    12/2/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $GTBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

      Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts. SAN FRANCISCO, CALIFORNIA, May 19, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced successful completion of dosing in Cohort 1 and subsequent initiation of dosing in Cohort 2 of its Phase 1 dose escalatio

      5/19/25 9:00:00 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GT Biopharma Appoints New Member to its Board of Directors

      SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a

      5/14/25 7:00:00 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit

      SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Jeffrey Miller, MD1 from the University of Minnesota Medical School2 will participate as an expert speaker at the 10th Anniversary of the Innate Killer Summit being held March 3-5, 2025 in San Diego, CA. 10th Anniversary of the Innate Killer Summit Title:Showcasing Advantages of Tri-Specific Killer Engagers to Turbocharge NK Recruitment & PotencyDate:Tuesday, March 4, 2025Time:1:30 pm PTP

      3/4/25 7:00:00 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTBP
    SEC Filings

    See more
    • SEC Form 10-Q filed by GT Biopharma Inc.

      10-Q - GT Biopharma, Inc. (0000109657) (Filer)

      5/15/25 3:35:22 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GT Biopharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - GT Biopharma, Inc. (0000109657) (Filer)

      5/13/25 4:05:10 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GT Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - GT Biopharma, Inc. (0000109657) (Filer)

      5/13/25 9:01:14 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on GT Biopharma with a new price target

      ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00

      12/2/24 10:00:20 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on GT Biopharma with a new price target

      HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00

      5/24/21 6:11:36 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on GT Biopharma with a new price target

      B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00

      4/13/21 6:45:30 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

      SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

      5/23/24 8:31:08 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GT Biopharma Inc. (Amendment)

      SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

      2/14/24 2:46:25 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GT Biopharma Inc.

      SC 13G - GT Biopharma, Inc. (0000109657) (Subject)

      9/19/23 11:56:06 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Urban Alan Louis

      4 - GT Biopharma, Inc. (0000109657) (Issuer)

      10/21/24 9:13:40 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Urban Alan Louis

      3 - GT Biopharma, Inc. (0000109657) (Issuer)

      6/13/24 4:14:29 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Breen Michael Martin was granted 200,000 shares, increasing direct ownership by 30% to 856,218 units

      4 - GT Biopharma, Inc. (0000109657) (Issuer)

      8/15/23 7:29:58 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GTBP
    Leadership Updates

    Live Leadership Updates

    See more

    $GTBP
    Financials

    Live finance-specific insights

    See more
    • GT Biopharma Appoints New Member to its Board of Directors

      SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a

      5/14/25 7:00:00 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GT Biopharma Appoints Manu Ohri as Chief Financial Officer

      BRISBANE, Calif., Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately. Mr. Ohri, an accomplished accounting and finance executive brings to GT Biopharma over 25 years of management, finance and public accounting experience in working with Boar

      2/18/22 7:30:00 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GT Biopharma Announces Executive Leadership Transition to Implement Next Phase of Strategic Journey

      BEVERLY HILLS, Calif., Nov. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary Tri-specific natural killer (NK) cell engager, TriKE® platform, today announced a restructuring of its executive management team. Mr. Anthony Cataldo, Chairman and Chief Executive Officer and Mr. Michael Handelman, Chief Financial Officer will both pursue other interests. The Board has appointed Dr. Gregory Berk as interim CEO, and Dr. Gavin Choy as acting CFO. Michael Breen has assumed the role of Executive Chairman of the Board, Chair of the Audit Committee and will ove

      11/8/21 7:30:00 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Peter Derycz and Bristol Investment Fund Ltd. Issue Open Letter to Research Solutions, Inc. Shareholders

      Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t

      8/4/23 9:30:41 AM ET
      $GTBP
      $RSSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Business Services
      Consumer Discretionary
    • GT BioPharma to Host a Management Update Conference Call

      BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30th at 4:30PM Eastern Time. To join the live webcast of the call and view the accom

      11/24/21 4:05:00 PM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GT Biopharma Provides Second Quarter 2021 Business Update

      BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021. "I am pleased with the corporate and clinical development milestones that GT Biopharma continues to achieve throughout the first half of 2021," said Anthony J. Catal

      8/13/21 7:30:00 AM ET
      $GTBP
      Biotechnology: Pharmaceutical Preparations
      Health Care